Last updated: October 9, 2026
SIRTURO, the brand name for bedaquiline fumarate, is a specialized anti-tuberculosis drug marketed by Johnson & Johnson through Janssen Pharmaceuticals. Its commercial value is driven less by retail prescriptions than by government tenders, Global Fund procurement, and treatment programs for multidrug-resistant or rifampicin-resistant tuberculosis (MDR/RR-TB).
The product’s core U.S. composition patent expired in late 2023, while regulatory exclusivity expired earlier. The commercial outlook now depends on secondary patents, generic entry, global access agreements, and the adoption of shorter all-oral MDR-TB regimens that use bedaquiline as a central component. SIRTURO remains clinically important, but its revenue base is modest relative to major specialty and oncology products.
What is SIRTURO and how does it generate revenue?
SIRTURO contains bedaquiline, a diarylquinoline that inhibits mycobacterial ATP synthase. The U.S. Food and Drug Administration approved it in 2012 for adults with pulmonary MDR-TB as part of combination therapy. The label was later expanded to include pediatric patients aged 5 years and older weighing at least 15 kilograms, using tablets or dispersible formulations depending on age and weight.[1]
SIRTURO is not normally prescribed as monotherapy. Its commercial demand is linked to:
- MDR-TB and rifampicin-resistant TB treatment programs.
- National tuberculosis programs.
- Global Fund and United States government procurement.
- Hospital and specialist infectious-disease channels.
- Fixed-duration combination regimens such as BPaLM and BPaL.
The product has a concentrated customer base. Public-sector purchasers and international development organizations account for a large portion of global demand. That structure limits pricing power but supports relatively stable volume when tuberculosis treatment guidelines favor bedaquiline.
SIRTURO product profile
| Attribute |
Detail |
| Active ingredient |
Bedaquiline fumarate |
| Brand |
SIRTURO |
| Original developer |
Tibotec, later Janssen Pharmaceuticals |
| Current commercial group |
Johnson & Johnson Innovative Medicine |
| U.S. approval |
December 2012 |
| U.S. application |
NDA 204384 |
| Initial indication |
Pulmonary multidrug-resistant tuberculosis |
| U.S. dosage forms |
20 mg and 100 mg tablets; pediatric dispersible formulation |
| FDA pathway |
Accelerated approval |
| Main market |
MDR/RR-TB |
| Principal alternatives |
Delamanid, linezolid, pretomanid, moxifloxacin, clofazimine |
| Key commercial channel |
Public-sector and donor-funded procurement |
How large is the SIRTURO market?
SIRTURO operates in a narrow market with a large untreated disease burden. The World Health Organization estimated approximately 410,000 incident MDR/RR-TB cases globally in 2022 and about 400,000 cases in 2023. The number of patients diagnosed and started on treatment remains materially lower than the estimated disease burden.[2,3]
That gap creates long-term volume potential, but the addressable market is constrained by diagnostic capacity, treatment infrastructure, drug budgets, and public-health policy. Unlike most specialty medicines, SIRTURO demand does not track conventional commercial measures such as private insurance coverage or physician promotion.
The product’s market position improved after bedaquiline became a preferred component of shorter, all-oral MDR-TB regimens. WHO guidance has moved away from injectable agents and toward regimens that include bedaquiline, linezolid, fluoroquinolones, and, in selected patients, pretomanid.[4]
Major demand drivers
| Driver |
Effect on SIRTURO |
| Rising MDR/RR-TB diagnosis |
Increases eligible treatment volume |
| Shorter all-oral regimens |
Supports bedaquiline use |
| WHO guideline inclusion |
Expands procurement eligibility |
| Global Fund purchasing |
Supports predictable public-sector demand |
| Generic competition |
Reduces price and J&J revenue per treatment course |
| Donor budget constraints |
Limits total market expansion |
| Cardiac safety monitoring |
Can restrict use in some patients |
| Local manufacturing |
Accelerates substitution for branded supply |
Bedaquiline also benefits from regimen-level demand. In a six-month BPaLM regimen, bedaquiline is used with pretomanid, linezolid, and moxifloxacin. As countries implement this approach, bedaquiline demand can increase even if the branded product loses share.
What has been SIRTURO’s financial trajectory?
J&J does not report SIRTURO as a separately managed public company, and its annual disclosures provide limited product-level detail. Public company filings and market data indicate annual SIRTURO sales in the approximate range of $200 million to $300 million during the early 2020s. Revenue has been relatively stable compared with products exposed to conventional generic substitution, but the mix is increasingly affected by public-sector pricing and generic supply.[5]
Indicative SIRTURO revenue trajectory
| Period |
Approximate global revenue profile |
Principal factor |
| 2018-2020 |
Approximately $200 million to $230 million annually |
Expansion of MDR-TB use |
| 2021 |
Approximately $230 million to $260 million |
Higher treatment activity and procurement |
| 2022 |
Approximately $250 million to $300 million |
Continued bedaquiline-centered regimen adoption |
| 2023 |
Approximately $250 million to $300 million |
Patent transition and public-sector access pressure |
| 2024 onward |
Downward pressure on branded revenue |
Generic entry and non-enforcement arrangements |
The precise annual figure depends on whether sales are presented by geographic region, product grouping, or continuing operations. The broader financial conclusion is consistent: SIRTURO is a meaningful specialty product for J&J but not a major contributor to consolidated revenue. Its commercial importance is greater in global infectious-disease strategy than in J&J’s overall earnings.
Revenue exposure by market type
High-income markets contribute relatively limited volume because MDR-TB incidence is low. Lower-income and middle-income countries account for much of the clinical need, but those markets generally have lower net pricing.
This creates a structural revenue tradeoff:
- Broader access increases patient volume.
- Public tenders compress net price.
- Generic products reduce branded share.
- Regimen adoption can offset part of the unit-price decline.
The result is likely to be a gradual erosion of branded revenue rather than an immediate collapse, particularly because procurement systems may continue purchasing SIRTURO where supply reliability, registration, or donor eligibility favors the originator.
When does SIRTURO lose exclusivity?
SIRTURO’s five-year new chemical entity exclusivity expired in 2017. FDA pediatric exclusivity added six months to applicable exclusivity periods, but it did not create a long new commercial monopoly.
The principal U.S. composition patent associated with bedaquiline is U.S. Patent No. 7,985,772. Its term extended into late 2023, subject to applicable patent-term adjustments and regulatory calculations. That date marked the end of the most important U.S. composition-of-matter barrier.[6]
SIRTURO exclusivity timeline
| Event |
Date |
| FDA approval |
December 2012 |
| NCE exclusivity |
Expired in 2017 |
| Pediatric extension |
Applied to eligible exclusivity periods |
| Core U.S. composition patent |
Expired in late 2023 |
| Generic competition |
Began expanding during the 2023-2024 period |
| Current commercial protection |
Secondary patents, regulatory barriers, supply agreements, and brand recognition |
Patent expiry does not automatically create immediate generic substitution. Generic launch timing depends on ANDA filing, Paragraph IV certifications, FDA approval, manufacturing capacity, local registration, donor procurement rules, and the existence of secondary patents.
What patents protect SIRTURO?
The SIRTURO patent estate has historically included several layers:
- Composition-of-matter protection for diarylquinoline compounds.
- Bedaquiline-specific compound claims.
- Salt and crystalline-form claims.
- Pharmaceutical composition claims.
- Tablet and dosage-form claims.
- Pediatric formulations.
- Methods of treating drug-resistant tuberculosis.
- Combination-treatment claims.
The strongest historical protection was the core compound patent. Secondary patents generally have narrower claim scope and are more vulnerable to validity and non-infringement challenges.
Patent protection by technical category
| Patent category |
Commercial purpose |
Relative strength |
| Core compound |
Blocks use of bedaquiline itself |
Historically strongest |
| Fumarate salt |
Protects commercial active form |
Moderate |
| Crystal or solid form |
Protects manufacturing and stability attributes |
Moderate to narrow |
| Tablet formulation |
Covers dosage-form implementation |
Narrower |
| Pediatric formulation |
Supports age-specific product |
Narrow |
| Method of treatment |
Protects selected regimens or patient populations |
Depends on claim construction |
| Combination therapy |
Covers use with companion agents |
Narrow and jurisdiction-dependent |
Secondary patents may delay a particular generic formulation, but they are less likely to preserve broad market exclusivity if a competitor can use a different salt, manufacturing process, formulation, or treatment method.
What is the Orange Book status of SIRTURO?
SIRTURO is listed in the FDA’s Orange Book under NDA 204384. The Orange Book records approved product information and patents submitted by the NDA holder for listing against approved drug products.[7]
The most important Orange Book issue is whether any unexpired listed patent remains capable of delaying ANDA approval or supporting a patent-infringement action. After expiration of the core composition patent, the commercial relevance of any remaining listing depends on:
- The precise claims in the listed patent.
- The dosage form covered.
- The generic applicant’s Paragraph IV certification.
- Whether the applicant uses an alternative formulation.
- Whether the NDA holder files an infringement action within the statutory period.
An Orange Book listing is not the same as a finding that the patent is valid or infringed. A generic applicant can challenge listed patents through a Paragraph IV certification.
Which companies are challenging SIRTURO exclusivity?
Generic and public-health suppliers have pursued bedaquiline products for international markets. The competitive field includes companies such as Lupin, Macleods Pharmaceuticals, Viatris and other manufacturers supplying national programs, procurement organizations, or regulated markets.
The global competitive process is fragmented because FDA approval, WHO prequalification, national marketing authorization, and donor eligibility are separate milestones. A company may be commercially active in low- and middle-income countries without having an approved U.S. ANDA.
Generic entry channels
| Channel |
Relevance |
| U.S. ANDA approval |
Permits U.S. commercial launch after patent and exclusivity barriers |
| WHO prequalification |
Supports international procurement |
| National regulatory approval |
Enables country-level sales |
| Global Drug Facility procurement |
Provides access to public TB programs |
| Voluntary licensing |
Reduces litigation and registration barriers |
| Non-enforcement commitments |
Permit generic supply in specified territories |
No broad, high-profile U.S. Paragraph IV litigation campaign has reshaped the SIRTURO market in the manner seen with major cardiovascular, oncology, or immunology drugs. The more important competitive event has been international generic access and the weakening of originator control over public-sector supply.
How do licensing agreements affect SIRTURO?
J&J has faced sustained pressure to expand access to bedaquiline in high-burden countries. The company has used pricing, supply, and non-enforcement mechanisms rather than relying solely on conventional exclusivity.
In 2023, J&J announced measures intended to prevent its secondary patents from blocking generic bedaquiline in a large group of low- and middle-income countries. The Stop TB Partnership and related procurement organizations supported arrangements designed to increase the number of qualified suppliers.[8]
These arrangements have three commercial effects:
- They reduce the probability of prolonged branded exclusivity in priority TB markets.
- They improve supply security for governments and donors.
- They shift competition from patent litigation toward price, quality, registration, and manufacturing capacity.
Licensing access does not eliminate all barriers. Generic manufacturers still need validated production, regulatory approval, pharmacovigilance systems, and procurement qualification. However, non-enforcement materially lowers the legal risk of entering covered countries.
What patent litigation and settlement risks affect SIRTURO?
SIRTURO faces a lower litigation profile than high-revenue small-molecule products because the market is concentrated in public-sector procurement and the core patent has expired. Potential disputes may still involve:
- Paragraph IV challenges to listed patents.
- Validity challenges against secondary formulation or salt patents.
- Manufacturing-process disputes.
- Royalty or license interpretation.
- Territorial scope of non-enforcement commitments.
- Product quality or bioequivalence disputes.
Settlement agreements could delay generic entry in a specific jurisdiction, but the commercial value of a settlement is limited by the humanitarian nature of the market and the availability of non-U.S. suppliers. A settlement that preserves U.S. launch timing would not necessarily protect J&J revenue in countries where generic competition is already authorized.
How strong is the SIRTURO patent estate?
The estate is materially weaker after expiry of the core compound patent. Its remaining strength is best described as selective rather than broad.
Strength assessment
| Factor |
Assessment |
| Core molecule protection |
Expired in the United States |
| Regulatory exclusivity |
Expired |
| Secondary formulation protection |
Potentially relevant but narrow |
| Method-of-use protection |
Dependent on claim scope and jurisdiction |
| Manufacturing barriers |
Meaningful for quality-sensitive production |
| Clinical position |
Strong because bedaquiline is guideline-preferred |
| Generic substitution risk |
High in public-sector markets |
| Brand resilience |
Moderate where procurement values continuity |
| Litigation leverage |
Lower than during compound-patent life |
The clinical position is stronger than the legal position. Bedaquiline remains important in MDR-TB treatment even as generic manufacturers enter. This distinction matters for investment analysis: erosion of branded sales does not imply erosion of bedaquiline utilization.
What is the FDA regulatory status of SIRTURO?
The FDA granted accelerated approval based on sputum culture conversion and the product’s role in treating a serious disease with limited therapeutic alternatives.[1] The product carries significant safety considerations, including QT prolongation and the need to consider interactions with other QT-prolonging medicines.
Regulatory risk is linked to:
- Confirmatory evidence requirements.
- Postmarketing commitments.
- Pediatric formulations.
- Drug-drug interactions.
- Hepatic safety.
- QT interval effects.
- Label changes affecting combination regimens.
SIRTURO’s regulatory position is stronger than its patent position because the drug is embedded in established treatment guidelines and clinical practice. Generic products must demonstrate pharmaceutical equivalence and bioequivalence, but they do not need to repeat the entire originator clinical-development program under the ANDA pathway.
How does SIRTURO compare with competing TB drugs?
| Drug |
Role in MDR/RR-TB |
Commercial position |
| Bedaquiline |
Core agent in many all-oral regimens |
Strong clinical demand; high generic risk |
| Pretomanid |
Used in selected BPaL/BPaLM regimens |
Narrower regimen-specific market |
| Linezolid |
Important companion drug |
Older generic product with broad suppliers |
| Delamanid |
Alternative anti-TB agent |
Smaller commercial footprint |
| Moxifloxacin |
Fluoroquinolone component |
Generic and widely available |
| Clofazimine |
Companion agent in some regimens |
Established low-cost supply |
SIRTURO’s main competitive advantage is regimen centrality. Delamanid and pretomanid compete at the regimen level, but neither has displaced bedaquiline as the principal anchor of modern MDR-TB treatment.
What generic launch scenarios exist for SIRTURO?
Scenario 1: Gradual public-sector substitution
This is the most likely scenario. Generic suppliers gain approval and procurement eligibility, while J&J retains some branded volume in countries with slower registration or supply preferences. Branded revenue declines gradually.
Scenario 2: Rapid tender-driven erosion
Large donor-funded tenders select the lowest-cost qualified supplier. SIRTURO volume falls quickly in high-burden countries, with J&J retaining limited premium or continuity business.
Scenario 3: Brand retention in regulated markets
Generic uptake remains slower in the United States, Europe, Japan, and selected middle-income markets because of regulatory timing, procurement practices, or limited MDR-TB volume. Global revenue still declines because most addressable patients are outside those markets.
Scenario 4: Volume growth offsets price erosion
More patients receive shorter bedaquiline-containing regimens, increasing total treatment volume. Generic competition reduces J&J’s share and price, but the overall bedaquiline market expands.
The fourth scenario is clinically favorable but financially less favorable for J&J unless the company retains a meaningful share through supply agreements, quality differentiation, or procurement relationships.
What geographic coverage does SIRTURO have?
SIRTURO has global regulatory and procurement relevance, but patent and commercial conditions vary by country.
| Region |
Market characteristics |
| United States |
Low patient volume; Orange Book and ANDA dynamics are important |
| European Union |
National procurement and MDR-TB incidence determine volume |
| India |
Large TB burden; strong generic manufacturing base |
| Southeast Asia |
High treatment need and donor-funded procurement |
| Sub-Saharan Africa |
High public-health need; price and supply access dominate |
| Latin America |
Country-specific registration and tender systems |
| Central Asia and Eastern Europe |
Significant MDR-TB burden and public procurement dependence |
The countries with the greatest epidemiological need are also among the markets most exposed to generic competition. This limits J&J’s ability to convert global clinical importance into high-margin branded sales.
What manufacturing and intellectual-property barriers remain?
Manufacturing bedaquiline at commercial scale requires control of chemical synthesis, impurity profiles, solid-state properties, stability, and tablet performance. These barriers can delay entrants even after patent expiry.
The remaining barriers include:
- Active pharmaceutical ingredient qualification.
- Consistent fumarate or alternative salt production.
- Bioequivalence testing.
- Stability data.
- Pediatric dispersible-tablet development.
- WHO prequalification.
- National registration.
- Donor procurement approval.
- Pharmacovigilance and batch-release systems.
These constraints favor manufacturers with established anti-infective operations and international regulatory experience. They also make supply reliability a competitive factor alongside price.
What is the revenue exposure for Johnson & Johnson?
SIRTURO is strategically important but financially small relative to J&J’s total pharmaceutical portfolio. Its annual revenue is measured in hundreds of millions of dollars, while J&J’s total pharmaceutical sales are measured in tens of billions.[5]
The principal financial risks are:
- Loss of branded share after core patent expiry.
- Price reductions in donor-funded markets.
- Generic competition from India-based manufacturers.
- Non-enforcement of secondary patents.
- Public procurement consolidation.
- Substitution by alternative regimens in some patients.
Potential offsets include:
- Growth in MDR-TB diagnosis and treatment.
- Expanded use of shorter all-oral regimens.
- Continued demand for reliable branded supply.
- New pediatric and dispersible formulations.
- Procurement agreements in markets without immediate generic substitution.
SIRTURO is therefore unlikely to create a material consolidated earnings shock for J&J. It is more relevant to infectious-disease portfolio strategy, global access policy, and the competitive positioning of bedaquiline-based treatment.
Key Takeaways
- SIRTURO is bedaquiline fumarate, a central drug in modern MDR/RR-TB treatment.
- Its U.S. NCE exclusivity expired in 2017, and the core composition patent expired in late 2023.
- The commercial market is driven by public procurement, donor funding, and WHO treatment guidelines.
- Annual sales were broadly in the $200 million to $300 million range during the early 2020s.
- Generic competition is likely to reduce branded revenue, especially in high-burden low- and middle-income countries.
- Bedaquiline utilization can continue to grow even as SIRTURO branded sales decline.
- The patent estate is weaker after core compound expiry, with remaining protection concentrated in formulations, salts, methods, and manufacturing.
- No major U.S. Paragraph IV litigation campaign has become the defining market event.
- J&J’s global-access and non-enforcement arrangements reduce legal barriers for generic supply.
- The main investment question is not whether bedaquiline remains clinically relevant. It is how quickly generic procurement converts clinical demand into non-branded volume.
FAQs
Is SIRTURO still patent protected?
The core U.S. composition patent expired in late 2023. Secondary patents may remain relevant for specific formulations, salts, methods, or jurisdictions.
Can generic bedaquiline replace SIRTURO?
Yes. Generic substitution is most likely in public-sector and donor-funded markets, subject to national approval, WHO qualification, and procurement eligibility.
Does SIRTURO have biologic or biosimilar competition?
No. SIRTURO is a small-molecule drug. Its competitors are chemically synthesized generic bedaquiline products and alternative anti-TB medicines, not biosimilars.
Does SIRTURO have pediatric market protection?
Pediatric approval and formulation protection support regulatory and commercial positioning, but they do not recreate broad compound exclusivity after expiry of the core patent.
Will the BPaLM regimen increase SIRTURO sales?
BPaLM can increase total bedaquiline demand because bedaquiline is a core component. The effect on J&J revenue depends on whether treatment growth is captured by SIRTURO or generic suppliers.
References
-
U.S. Food and Drug Administration. (2024). SIRTURO (bedaquiline fumarate) prescribing information. FDA.
-
World Health Organization. (2023). Global tuberculosis report 2023. World Health Organization.
-
World Health Organization. (2024). Global tuberculosis report 2024. World Health Organization.
-
World Health Organization. (2022). WHO consolidated guidelines on tuberculosis: Module 4, treatment - drug-resistant tuberculosis treatment. World Health Organization.
-
Johnson & Johnson. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. Johnson & Johnson.
-
U.S. Patent and Trademark Office. (2024). Patent term and patent information for U.S. Patent No. 7,985,772. USPTO.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
-
Stop TB Partnership. (2023). Global access and procurement information for bedaquiline. Stop TB Partnership.